J&J’s MonumenTAL-3 Data Rewrites the Myeloma Playbook Before the Ink Dries on DPd
MonumenTAL-3 delivers 81.3% PFS at 24 months for talquetamab plus daratumumab, threatening DPd's grip on earlier RRMM treatment lines.
Oncology Pipeline
AbbVie’s Skyrizi Machine Is Writing Checks Its Oncology Pipeline Now Has to Cash
Skyrizi hit $4.48B in Q1 2026 revenue. AbbVie is deploying that cash into oncology—and the CLL14 nine-year data just...
Lilly’s $2.3B JAK2 Bet Just Showed Its First Cards — and the Myelofibrosis Market Won’t Be the Same
Lilly's AJ1-11095 hit 70% spleen volume reduction in post-ruxolitinib patients at EHA 2026, threatening Incyte's $1.5B ruxolitinib franchise with...
J&J’s PROTEUS Data Doesn’t Just Beat the Standard of Care — It Buries It
J&J's Phase 3 PROTEUS trial shows apalutamide before and after surgery cuts metastasis or death risk in high-risk prostate...
Ovarian Cancer’s PARP Inhibitor Gold Rush Is Over — What Comes Next Will Separate the Winners From the Wreckage
PARP inhibitors reshaped ovarian cancer treatment, but with olaparib holding 38% market share and biomarker limits exposed, the next...
The FDA Just Validated a $1.6 Billion Platform — and the Real Winner Isn’t Pfizer
FDA's May 2026 approval of Veppanu, the first PROTAC drug, validates targeted protein degradation as a platform — and...
Coultreon’s $125M Bet Proves the Real Alpha in Biotech Is Knowing Which Shipwrecks Are Worth Salvaging
Coultreon Biopharma raised $125M Series A for rescued Galapagos oncology assets — and the investor syndicate tells you exactly...
Novartis Is Buying the Next Generation of PI3Kα — Before the Current Generation Has Finished Paying Off
Novartis's acquisition of SNV4818 from Synnovation Therapeutics isn't a gap-fill — it's a calculated preemption. In a breast cancer...